Zhende Medical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	4,306	4,247	4,105	6,131	4,907	10,311
Other Revenue	16.67	16.67	21.6	6.47	184.42	87.78
Revenue	4,323	4,264	4,127	6,138	5,092	10,399
Revenue Growth (YoY)	6.91%	3.32%	-32.76%	20.54%	-51.04%	456.75%
Cost of Revenue	2,917	2,850	2,850	4,063	3,353	5,568
Gross Profit	1,405	1,414	1,277	2,075	1,738	4,830
Selling, General & Admin	923.41	890.18	894.44	984.23	808.32	878.48
Research & Development	136.13	135.49	138.95	227	153.14	259.71
Other Operating Expenses	18.72	2.92	8.15	41.8	48.33	28.17
Operating Expenses	1,084	1,039	1,043	1,262	1,011	1,184
Operating Income	321.47	375.05	233.3	812.89	727.2	3,646
Interest Expense	-29.84	-28.73	-28.93	-33.54	-25.07	-18.32
Interest & Investment Income	24.59	35.92	46.76	10.61	52.4	26.63
Currency Exchange Gain (Loss)	24.3	24.3	11.76	21.89	-15.69	-94.42
Other Non Operating Income (Expenses)	11.85	-2.87	-1.98	-1.03	-2.07	-4.52
EBT Excluding Unusual Items	352.37	403.68	260.9	810.81	736.77	3,555
Impairment of Goodwill	-	-	-2.29	-3.91	-	-
Gain (Loss) on Sale of Investments	-6.61	-12.25	-21.06	-71.06	-2.7	-2.84
Gain (Loss) on Sale of Assets	-4.94	93.43	-15.96	-13.53	-0.61	0.04
Asset Writedown	3.86	-9.09	-52.02	-4.97	-3.31	-48.4
Other Unusual Items	-1.21	-0.31	49.34	84.38	89.81	28.8
Pretax Income	343.47	475.46	218.89	801.72	819.95	3,533
Income Tax Expense	53.19	78.25	5.49	99.96	99	561.19
Earnings From Continuing Operations	290.28	397.21	213.4	701.76	720.95	2,972
Minority Interest in Earnings	-9.38	-12.04	-15	-21.88	-125.08	-422.45
Net Income	280.9	385.17	198.4	679.88	595.86	2,549
Net Income to Common	280.9	385.17	198.4	679.88	595.86	2,549
Net Income Growth	36.80%	94.14%	-70.82%	14.10%	-76.63%	1524.99%
Shares Outstanding (Basic)	266	266	268	237	226	204
Shares Outstanding (Diluted)	266	266	268	237	227	204
Shares Change (YoY)	-1.31%	-0.92%	13.18%	4.56%	11.08%	4.00%
EPS (Basic)	1.06	1.45	0.74	2.87	2.64	12.50
EPS (Diluted)	1.06	1.45	0.74	2.87	2.63	12.50
EPS Growth	38.62%	95.95%	-74.22%	9.13%	-78.96%	1462.50%
Free Cash Flow	-129.63	-308.55	-147.13	491.92	122.16	2,028
Free Cash Flow Per Share	-0.49	-1.16	-0.55	2.08	0.54	9.94
Dividend Per Share	0.650	0.650	1.250	-	0.600	2.300
Dividend Growth	30.00%	-48.00%	-	-	-73.91%	648.94%
Gross Margin	32.51%	33.16%	30.93%	33.80%	34.14%	46.45%
Operating Margin	7.44%	8.80%	5.65%	13.24%	14.28%	35.06%
Profit Margin	6.50%	9.03%	4.81%	11.08%	11.70%	24.52%
Free Cash Flow Margin	-3.00%	-7.24%	-3.56%	8.02%	2.40%	19.50%
EBITDA	554.55	612.37	476.27	998.26	858.7	3,725
EBITDA Margin	12.83%	14.36%	11.54%	16.27%	16.86%	35.82%
D&A For EBITDA	233.09	237.32	242.97	185.38	131.51	78.57
EBIT	321.47	375.05	233.3	812.89	727.2	3,646
EBIT Margin	7.44%	8.80%	5.65%	13.24%	14.28%	35.06%
Effective Tax Rate	15.49%	16.46%	2.51%	12.47%	12.07%	15.88%
Revenue as Reported	4,323	4,264	4,127	6,138	5,092	10,399
Advertising Expenses	-	42.83	38.17	39.94	20.1	49.07

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.